Alkermes PLC
(STU:8AK)
€
23.2
0.6 (2.65%)
Market Cap: 3.85 Bil
Enterprise Value: 3.50 Bil
PE Ratio: 9.65
PB Ratio: 3.29
GF Score: 62/100 - Q1 2024 Alkermes Plc Earnings Call TranscriptMay 01, 2024Earnings
- Q4 2023 Alkermes Plc Earnings Call TranscriptFeb 15, 2024€26 (+3.17%)Earnings
- Alkermes Plc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Alkermes Plc at Evercore ISI HealthCONx Conference TranscriptNov 29, 2023
- Alkermes Plc at Piper Sandler Healthcare Conference TranscriptNov 28, 2023
- Q3 2023 Alkermes Plc Earnings Call TranscriptOct 25, 2023€22.11 (+0.85%)Earnings
- Alkermes Plc Mural Oncology Call TranscriptOct 17, 2023
- Alkermes Plc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Alkermes Plc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Q2 2023 Alkermes Plc Earnings Call TranscriptJul 26, 2023€25.08 (-2.88%)Earnings
- Alkermes Plc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Alkermes Plc Investor Update Call TranscriptJun 06, 2023
- Q1 2023 Alkermes Plc Earnings Call TranscriptApr 26, 2023€25.45 (+1.48%)Earnings
- Q4 2022 Alkermes Plc Earnings Call TranscriptFeb 16, 2023€24.03 (+2.31%)Earnings
- Alkermes Plc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Alkermes Plc at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Alkermes Plc Earnings Call TranscriptNov 02, 2022€21.44 (-1.07%)Earnings
- Q2 2022 Alkermes Plc Earnings Call TranscriptJul 27, 2022€26.77 (+2.73%)Earnings
- Alkermes Plc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Alkermes Plc ARTISTRY-1 Data Call at ASCO TranscriptJun 06, 2022
- Q1 2022 Alkermes Plc Earnings Call TranscriptApr 27, 2022€23.61 (-3.37%)Earnings
- Q4 2021 Alkermes Plc Earnings Call TranscriptFeb 16, 2022€18.95Earnings
- Alkermes Plc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Alkermes Plc Investor Update Call TranscriptNov 08, 2021
- Q3 2021 Alkermes Plc Earnings Call TranscriptOct 27, 2021€23.04 (-8.15%)Earnings
- Alkermes Plc at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Alkermes Plc Earnings Call TranscriptJul 28, 2021€19.51 (+5.53%)Earnings
- Alkermes Plc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Alkermes Plc Investor Event at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting TranscriptJun 04, 2021
- Alkermes Plc Approval of LYBALVI - Conference Call TranscriptJun 01, 2021
- Alkermes Plc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 12, 2021
- Q1 2021 Alkermes Plc Earnings Call TranscriptApr 28, 2021€17.19 (-1.07%)Earnings
- Alkermes Plc at Stifel CNS Day TranscriptApr 01, 2021
- Alkermes Plc Virtual Investor Day TranscriptMar 25, 2021
- Alkermes Plc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 24, 2021
- Q4 2020 Alkermes Plc Earnings Call TranscriptFeb 11, 2021€17.46 (-2.59%)Earnings
- Alkermes Plc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Alkermes Plc to Discuss Regulatory Update for ALKS 3831 - Conference Call TranscriptNov 17, 2020
- Q3 2020 Alkermes Plc Earnings Call TranscriptOct 29, 2020€14.58Earnings
- Alkermes Plc FDA Advisory Committee Review of New Drug Application for ALKS 3831 - Conference Call TranscriptOct 09, 2020
- Alkermes Plc Investor Event at the 2020 European Society for Medical Oncology Virtual Congress TranscriptSep 18, 2020
- Alkermes Plc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Q2 2020 Alkermes Plc Earnings Call TranscriptJul 29, 2020€15.14 (-6.32%)Earnings
- Alkermes Plc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Alkermes Plc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 13, 2020
- Q1 2020 Alkermes Plc Earnings Call TranscriptApr 29, 2020€13.84Earnings
- Alkermes Plc at Cowen HealthCare Conference TranscriptMar 02, 2020
- Alkermes Plc at Leerink Global Healthcare Conference TranscriptFeb 26, 2020
- Q4 2019 Alkermes Plc Earnings Call TranscriptFeb 13, 2020€16.07 (-0.57%)Earnings
- Alkermes Plc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Alkermes Plc at Evercore HealthCONx Conference TranscriptDec 03, 2019
- Alkermes Plc at Jefferies London Healthcare Conference TranscriptNov 21, 2019
- Alkermes Plc at Stifel Healthcare Conference TranscriptNov 19, 2019
- Q3 2019 Alkermes Plc Earnings Call TranscriptOct 23, 2019€15.89 (+3.01%)Earnings
- Alkermes Plc at Cantor Fitzgerald Global Healthcare Conference TranscriptOct 03, 2019
- Q2 2019 Alkermes Plc Earnings Call TranscriptJul 25, 2019€19.32 (+1.96%)Earnings
- Alkermes Plc at UBS Global Healthcare Conference TranscriptMay 20, 2019
- Q1 2019 Alkermes Plc Earnings Call TranscriptApr 25, 2019€28.61 (+0.65%)Earnings
- Alkermes Plc Webinar on ALKS 3831 ENLIGHTEN-2 Data TranscriptApr 12, 2019
- Alkermes Plc at Cowen Health Care Conference TranscriptMar 12, 2019
- Alkermes Plc at Leerink Partners Global Healthcare Conference TranscriptFeb 27, 2019
- Q4 2018 Alkermes Plc Earnings Call TranscriptFeb 14, 2019€25.83 (-4.14%)Earnings
Alkermes Plc at Evercore HealthCONx Conference Transcript
Dec 03, 2019 / 01:00PM GMT
Release Date Price:
€17
(-0.54%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Okay. Well, listen, thank you for being here, Richard. Good to have you to kick this conference off. I know there's a lot to discuss in a fairly limited amount of time.
Questions & Answers
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
But maybe just to start off, what's on the top of your mind now heading into 2020, given there's been a lot of announcements and it's been fairly eventful at Alkermes [recently]?
Richard F. Pops
Alkermes plc - Chairman & CEO
Well, first of all, thanks for having us, and good morning, Umer. Uncharacteristically for myself, the thing is, top of mind for me is actually stock price because we've been doing this, building this company for a number of years and are quite optimistic about all the elements that are in place. And when the stock has been so weak over the past year, we've
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)